You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Andrew Han covers breaking news for GenomeWeb. He tracks companies in the sequencing and diagnostic markets.
The US Federal Trade Commission's recent challenge raises the question who Illumina can acquire while remaining a quasi-monopolist for sequencing equipment.
Adaptive Cofounder and Chief Scientific Officer Harlan Robins compared the launch of the test to the unveiling of the Tesla Roadster electric sports car.
The company's nucleic acid extraction kits have offered labs relief from COVID-19-related shortages of traditional silica-based bind-wash-elute assays.
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.
Angstrom Bio is developing a rapid, scalable coronavirus test that uses nanopore sequencing to detect barcoded PCR products.
Adaptive is rebranding its immunoSeq Dx assay as T-Detect and plans to submit for an EUA for a COVID-19 T-Cell response test by the end of the year.
Illumina thinks the next-generation sequencing cancer testing market will grow to $75 billion over the next 15 years, driven by screening.
The firm is hoping that researcher-generated data will soon be published in peer-reviewed papers, while it weathers the COVID-19 pandemic.
The sequencing firm said infectious disease research, diagnostics, screening, and surveillance could all increase demand for its NGS products.
Company officials credited investments in information technology, as well as R&D for RT-PCR-based tests, with driving up the firm's billable testing numbers.